Study of WGI-0301 for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced liver cancer (HCC) that cannot be surgically removed or treated with local therapies.
- Your cancer has gotten worse or you could not tolerate at least one standard treatment (such as immunotherapy or a targeted drug).
- You have a tumor that can be measured on scans and has not been treated with local therapies like chemoembolization or ablation (unless it grew in that area).
- Your liver function is good enough (Child-Pugh class A or B with score 7 or less) and your blood work shows adequate organ function.
- You are willing to provide a tumor tissue sample if available, and agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (WGI-0301) combined with an existing liver cancer medicine (lenvatinib). It aims to see if the combination can help people with advanced liver cancer when other treatments haven't worked.
This study tests an experimental drug (WGI-0301) combined with an FDA-approved immunotherapy drug (nivolumab, also known as Opdivo) for advanced liver or kidney cancer. The goal is to see if this combination is safe and effective for patients whose cancer has either not responded to standard treatment or has not been treated yet.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.